KalVista Pharmaceuticals
KALV
KALV was delisted on the 10th of June, 2026.
91 hedge funds and large institutions have $234M invested in KalVista Pharmaceuticals in 2022 Q4 according to their latest regulatory filings, with 22 funds opening new positions, 27 increasing their positions, 29 reducing their positions, and 24 closing their positions.
1,124% more call options, than puts
Call options by funds: $1.1M | Put options by funds: $90K
7% less repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 29
8% less first-time investments, than exits
New positions opened: 22 | Existing positions closed: 24
2.76% less ownership
Funds ownership: 104.23% → 101.47% (-2.8%)
3% less funds holding
Funds holding: 94 → 91 (-3)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
34% less capital invested
Capital invested by funds: $357M → $234M (-$122M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
TCG Crossover Management
Palo Alto,
California
|
+$18.2M |
| 2 |
VA
VR Adviser
New York
|
+$15.6M |
| 3 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
+$8.93M |
| 4 |
TCM
Tang Capital Management
San Diego,
California
|
+$7.48M |
| 5 |
JFG
Jefferies Financial Group
New York
|
+$6.43M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$26.5M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$11.3M |
| 3 |
IBT
International Biotechnology Trust
London,
United Kingdom
|
-$4.59M |
| 4 |
VC
Vivo Capital
Palo Alto,
California
|
-$3.63M |
| 5 |
SCM
Suvretta Capital Management
New York
|
-$3.4M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
JF
101
Jump Financial
Chicago,
Illinois
| – | -$177K | -12,200 | Closed |
|
|
AC
102
Aristides Capital
Louisville,
Kentucky
| – | -$174K | -12,000 | Closed |
|
|
CSS
103
Cubist Systematic Strategies
Stamford,
Connecticut
| – | -$169K | -11,627 | Closed |
|
104
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
| – | -$147K | -10,156 | Closed |
|
105
Mirae Asset Global Investments
Seoul,
South Korea
| – | -$145K | -10,014 | Closed |
|
|
AGM
106
Alpine Global Management
New York
| – | -$145K | -10,000 | Closed |
|
107
US Bancorp
Minneapolis,
Minnesota
| – | -$43K | -2,984 | Closed |
|
|
S
108
SignatureFD
Atlanta,
Georgia
| – | -$8K | -548 | Closed |
|
|
TWA
109
TCI Wealth Advisors
Tucson,
Arizona
| – | -$5K | -360 | Closed |
|
|
CUAMC
110
China Universal Asset Management Company
Shanghai,
China
| – | -$3K | -230 | Closed |
|
111
Daiwa Securities Group
Tokyo,
Japan
| – | -$1K | -46 | Closed |
|
|
LC
112
Lindbrook Capital
Calabasas,
California
| – | -$1K | -42 | Closed |
|
KALV Hedge Fund Activity: Q4 2022 in Review
91 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in KalVista Pharmaceuticals (KALV) for Q4 2022, worth a combined $234M — down 34% from $357M a quarter earlier.
Sellers outnumbered buyers: 24 funds closed out of KALV and 22 opened new positions — a net loss of 2 holders — while 29 trimmed existing stakes and 27 added.
The largest buyer was TCG Crossover Management, opening a new position worth an estimated $18.2M. The largest seller was Deep Track Capital, exiting entirely with an estimated $26.5M sold.
- 91 institutional investors held KalVista Pharmaceuticals (KALV) as of Q4 2022, down from 94 in Q3 2022.
- Funds reported $234M of KalVista Pharmaceuticals stock for Q4 2022, down 34% quarter-over-quarter.
- 22 funds opened new KalVista Pharmaceuticals positions in Q4 2022 and 24 closed out, a net change of -2 holders.
- The largest KalVista Pharmaceuticals buyer in Q4 2022 was TCG Crossover Management, an estimated $18.2M added.
- The largest KalVista Pharmaceuticals seller in Q4 2022 was Deep Track Capital, an estimated $26.5M sold.
Based on aggregated 13F filings for Q4 2022.